AU679859B2 - Novel compound, process for producing the same, and antitumor agent - Google Patents

Novel compound, process for producing the same, and antitumor agent

Info

Publication number
AU679859B2
AU679859B2 AU25767/95A AU2576795A AU679859B2 AU 679859 B2 AU679859 B2 AU 679859B2 AU 25767/95 A AU25767/95 A AU 25767/95A AU 2576795 A AU2576795 A AU 2576795A AU 679859 B2 AU679859 B2 AU 679859B2
Authority
AU
Australia
Prior art keywords
hydrogen atom
producing
same
group
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU25767/95A
Other languages
English (en)
Other versions
AU2576795A (en
Inventor
Katsumi Chiba
Shigeki Kashimoto
Koh-Ichiro Shibamori
Kyoji Tomita
Yasunori Tsuzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Publication of AU2576795A publication Critical patent/AU2576795A/en
Application granted granted Critical
Publication of AU679859B2 publication Critical patent/AU679859B2/en
Assigned to DAINIPPON SUMITOMO PHARMA CO., LTD. reassignment DAINIPPON SUMITOMO PHARMA CO., LTD. Request to Amend Deed and Register Assignors: DAINIPPON PHARMACEUTICAL CO. LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU25767/95A 1994-06-14 1995-06-06 Novel compound, process for producing the same, and antitumor agent Expired AU679859B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP6-156578 1994-06-14
JP6-197921 1994-07-28
JP19792194 1994-07-28
JP30691494 1994-11-15
JP6-306914 1994-11-15
JP6-339956 1994-12-28
JP33995694 1994-12-28
JP8170595 1995-03-13
JP7-81705 1995-03-13
PCT/JP1995/001110 WO1995034559A1 (en) 1994-06-14 1995-06-06 Novel compound, process for producing the same, and antitumor agent

Publications (2)

Publication Number Publication Date
AU2576795A AU2576795A (en) 1996-01-05
AU679859B2 true AU679859B2 (en) 1997-07-10

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25767/95A Expired AU679859B2 (en) 1994-06-14 1995-06-06 Novel compound, process for producing the same, and antitumor agent

Country Status (26)

Country Link
US (1) US5817669A (cg-RX-API-DMAC7.html)
EP (1) EP0787726B1 (cg-RX-API-DMAC7.html)
JP (1) JP3391796B2 (cg-RX-API-DMAC7.html)
KR (1) KR100350921B1 (cg-RX-API-DMAC7.html)
CN (1) CN1053668C (cg-RX-API-DMAC7.html)
AT (1) ATE209645T1 (cg-RX-API-DMAC7.html)
AU (1) AU679859B2 (cg-RX-API-DMAC7.html)
BR (1) BR9508037A (cg-RX-API-DMAC7.html)
CA (1) CA2192824C (cg-RX-API-DMAC7.html)
CZ (1) CZ292631B6 (cg-RX-API-DMAC7.html)
DE (1) DE69524251T2 (cg-RX-API-DMAC7.html)
DK (1) DK0787726T3 (cg-RX-API-DMAC7.html)
ES (1) ES2163512T3 (cg-RX-API-DMAC7.html)
FI (1) FI112485B (cg-RX-API-DMAC7.html)
HU (1) HU220072B (cg-RX-API-DMAC7.html)
MX (1) MX9606331A (cg-RX-API-DMAC7.html)
NO (1) NO307255B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ287139A (cg-RX-API-DMAC7.html)
PL (1) PL181867B1 (cg-RX-API-DMAC7.html)
PT (1) PT787726E (cg-RX-API-DMAC7.html)
RO (1) RO117793B1 (cg-RX-API-DMAC7.html)
RU (1) RU2151770C1 (cg-RX-API-DMAC7.html)
SI (1) SI0787726T1 (cg-RX-API-DMAC7.html)
SK (1) SK281341B6 (cg-RX-API-DMAC7.html)
TW (1) TW319769B (cg-RX-API-DMAC7.html)
WO (1) WO1995034559A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002136A (es) 2001-09-26 2005-03-07 Bayer Pharmaceuticals Corp Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados.
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
WO2004091627A2 (en) * 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
AU2004272414B2 (en) * 2003-09-10 2009-05-28 Kyorin Pharmaceutical Co., Ltd. 7-(4-substituted 3- cyclopropylaminomethyl-1- pyrrolidinyl) quinolonecarboxylic acid derivative
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
AU2005222607B2 (en) * 2004-03-15 2010-11-25 Sunesis Pharmaceuticals, Inc. SNS-595 and methods of using the same
RU2405781C2 (ru) * 2004-10-14 2010-12-10 Ф.Хоффманн-Ля Рош Аг 1, 5-нафтиридиназолидиноны, обладающие cdk1 антипролиферативной активностью
US7501428B2 (en) * 2004-10-14 2009-03-10 Hoffmann-La Roche Inc. Quinazoline thiazolinones
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
CA2619663A1 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. Human ribosomal dna(rdna) and ribosomal rna (rrna) nucleic acids and uses thereof
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
KR20080041298A (ko) * 2005-09-02 2008-05-09 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
KR20170118936A (ko) * 2005-09-02 2017-10-25 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한 (＋)-1,4-디히드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
CN101305000A (zh) * 2005-09-14 2008-11-12 詹森药业有限公司 作为c-fms激酶抑制剂的5-氧代-5,8-二氢-吡啶并-嘧啶类
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en) * 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
MX2010004350A (es) * 2007-10-22 2010-05-19 Sunesis Pharmaceuticals Inc Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
AU2008335772B2 (en) 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
RU2558835C2 (ru) 2009-02-27 2015-08-10 Санесис Фармасьютикалз, Инк. Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
BR112013029201B1 (pt) 2011-05-13 2022-08-09 Array Biopharma Inc Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
AU2018238079B2 (en) * 2017-03-24 2022-03-03 Wakunaga Pharmaceutical Co., Ltd. Novel pyridone carboxylic acid derivative or salt thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63500518A (ja) * 1985-06-13 1988-02-25 シェリング・コ−ポレ−ション 多環式キノリン、ナフチリジンおよびピラジノピリジン誘導体
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
EP0154780B1 (en) * 1984-01-26 1990-04-11 Abbott Laboratories Quinoline antibacterial compounds
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
EP0226624A1 (en) * 1985-06-14 1987-07-01 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63500518A (ja) * 1985-06-13 1988-02-25 シェリング・コ−ポレ−ション 多環式キノリン、ナフチリジンおよびピラジノピリジン誘導体
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Also Published As

Publication number Publication date
HUT75777A (en) 1997-05-28
EP0787726A4 (cg-RX-API-DMAC7.html) 1997-08-06
SI0787726T1 (en) 2002-04-30
PL317726A1 (en) 1997-04-28
DE69524251T2 (de) 2002-07-11
SK157496A3 (en) 1997-08-06
KR100350921B1 (ko) 2002-11-18
HK1000495A1 (en) 2002-07-19
PL181867B1 (pl) 2001-09-28
CA2192824A1 (en) 1995-12-21
NO965305D0 (no) 1996-12-11
DE69524251D1 (de) 2002-01-10
CZ364396A3 (en) 1997-06-11
MX9606331A (es) 1997-03-29
CA2192824C (en) 2006-11-07
CN1053668C (zh) 2000-06-21
BR9508037A (pt) 1997-09-16
JP3391796B2 (ja) 2003-03-31
SK281341B6 (sk) 2001-02-12
NZ287139A (en) 1997-07-27
AU2576795A (en) 1996-01-05
HU220072B (hu) 2001-10-28
WO1995034559A1 (en) 1995-12-21
NO307255B1 (no) 2000-03-06
FI965020A7 (fi) 1996-12-16
ES2163512T3 (es) 2002-02-01
DK0787726T3 (da) 2002-02-11
HU9603455D0 (en) 1997-02-28
ATE209645T1 (de) 2001-12-15
RO117793B1 (ro) 2002-07-30
CZ292631B6 (cs) 2003-11-12
EP0787726B1 (en) 2001-11-28
NO965305L (no) 1997-02-04
EP0787726A1 (en) 1997-08-06
TW319769B (cg-RX-API-DMAC7.html) 1997-11-11
FI965020A0 (fi) 1996-12-13
PT787726E (pt) 2002-04-29
US5817669A (en) 1998-10-06
CN1158614A (zh) 1997-09-03
FI112485B (fi) 2003-12-15
RU2151770C1 (ru) 2000-06-27

Similar Documents

Publication Publication Date Title
AU679859B2 (en) Novel compound, process for producing the same, and antitumor agent
EP0945452A4 (en) SUGAR COMPOSITIONS, GELLING AGENTS, GELLING AGENT COMPOSITIONS, METHODS OF PREPARING SAME, AND GEL COMPOSITIONS
HUT70045A (en) 2-piperazinone derivatives parmaceutical compositions containing them and process for producing them
AU1039688A (en) 3(2h)pyridazinone, process for its preparation and antagonistic agent against srs-a containing it
HUT59378A (en) Process for producing urea derivatives and pharmaceutical compositions comprising such compounds
HUT47099A (en) Process for producing pyridine derivatives and pharmaceutical compositions comprising such compounds
AU7928791A (en) Bisphophonic acid derivatives, their production and use
PH24176A (en) New bicyclic compounds,process for preparation thereof and pharmaceutical composition comprising the same
NZ222185A (en) N-substituted methanesulphonamide derivatives, and anticancer compositions containing such
ATE148128T1 (de) Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung
AU1589695A (en) Bicyclic amino group-substituted pyridonecarboxylic acid derivatives, esters thereof and salts thereof, and bicyclic amines useful as intermediates thereof
DE3471654D1 (en) Ûbis(hydroxymethyl)-methyl¨-isoquinoline derivatives, process for preparing them and pharmaceutical compositions containing them
EP0590681A3 (en) A process for the preparation of aminothiadiazolylacetyl halide derivatives
EP0844247A4 (en) METHOD FOR PRODUCING 3-NORCEPHEMIC COMPOUNDS
EP0827961A4 (en) METHOD FOR PRODUCING BETA-LACTAM COMPOUNDS
GR3001003T3 (en) Novel pregnane derivatives, processes for their preparaton and pharmaceutical compositions containing same
ZA803682B (en) Clavulanic acid derivatives, a process for their preparation and their use